Dr. Honggang Bi is Senior Vice President, Drug Development Head, APAC, and General Manager, China.
Honggang provides executive oversight of both operations and customer relationships, representing Drug Development business lines, as well as LabCorp’s emerging Diagnostics presence in Asia Pacific (except India). Honggang drives enterprise growth strategies in the region, leveraging the Power of the Combined, with a particular focus on expansion in Japan, South Korea and other key markets in APAC region, in addition to China.
Honggang reports to Dr. Paul Kirchgraber, CEO of Drug Development and serves on the Drug Development Executive Committee and Global Operations Committee. Honggang works closely with global executives and country leaders to accelerate company’s commercial strategy, creating and building relationships with local customers as a priority. He strengthens a differentiated “one company” culture that provides continued opportunities for employees.
Since joining the company in 2007, Honggang has led the business growth in China, which has gained momentum in recent years, expanding services for local, regional and global customers. Prior to joining Covance, Honggang served as CEO of Frontage Laboratories. Since the early 1990s, Honggang has grown his career, with increasing responsibilities at biopharma companies such as SmithKline Beecham, Parke-Davis and Pfizer. Honggang brings a demonstrated track record of strong performance to the role, leveraging his unique mix of business acumen, scientific expertise and passion for people.